Loading...
SSKN logo

STRATA Skin Sciences, Inc.OTCPK:SSKN Stock Report

Market Cap US$887.6k
Share Price
US$0.15
US$10.8
98.6% undervalued intrinsic discount
1Y-94.2%
7D23.6%
1D
Portfolio Value
View

STRATA Skin Sciences, Inc.

OTCPK:SSKN Stock Report

Market Cap: US$887.6k

STRATA Skin Sciences (SSKN) Stock Overview

A medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. More details

SSKN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

SSKN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

STRATA Skin Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for STRATA Skin Sciences
Historical stock prices
Current Share PriceUS$0.15
52 Week HighUS$3.86
52 Week LowUS$0.11
Beta-0.054
1 Month Change0.53%
3 Month Change-39.46%
1 Year Change-94.18%
3 Year Change-98.39%
5 Year Change-98.92%
Change since IPO-99.90%

Recent News & Updates

Narrative Update Feb 15

SSKN: Future P/E Reassessment Will Create Opportunity Despite Nasdaq Delisting Risk

Analysts have revised their fair value estimate for STRATA Skin Sciences from $8.00 to $10.80, reflecting updated assumptions related to revenue growth, profit margin, a higher future P/E multiple, and a revised discount rate. What's in the News Nasdaq notified STRATA Skin Sciences that it is not in compliance with the minimum US$2,500,000 stockholders' equity requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1), and granted an extension until February 16, 2026, after accepting the company’s compliance plan submitted on September 19, 2025 (Key Developments).

Recent updates

Narrative Update Feb 15

SSKN: Future P/E Reassessment Will Create Opportunity Despite Nasdaq Delisting Risk

Analysts have revised their fair value estimate for STRATA Skin Sciences from $8.00 to $10.80, reflecting updated assumptions related to revenue growth, profit margin, a higher future P/E multiple, and a revised discount rate. What's in the News Nasdaq notified STRATA Skin Sciences that it is not in compliance with the minimum US$2,500,000 stockholders' equity requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1), and granted an extension until February 16, 2026, after accepting the company’s compliance plan submitted on September 19, 2025 (Key Developments).
Analysis Article Dec 19

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Oct 18

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Those holding STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shares would be relieved that the share price has rebounded...
Analysis Article Sep 03

There's No Escaping STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Muted Revenues Despite A 45% Share Price Rise

STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shares have had a really impressive month, gaining 45% after a shaky period...
Narrative Update Aug 16

CPT Reimbursement Expansion Will Augment Future Dermatology Opportunities

The consensus Analyst Price Target for STRATA Skin Sciences has been revised downward, primarily reflecting a notable decline in the Future P/E multiple, resulting in a reduction of fair value from $9.00 to $8.00. What's in the News STRATA Skin Sciences is collaborating with CMS to secure temporary reimbursement codes for its XTRAC excimer laser treatment, aiming to accelerate access to newly expanded reimbursement indications as early as the 2026 rule cycle.
Analysis Article Jul 03

Benign Growth For STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 0.3x STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) may be sending very bullish...
User avatar
New Narrative Apr 18

Improved XTRAC Utilization And Expanded International Partnerships Will Secure Success

Strategic removal of underperforming units and partnerships with clinics enhance device utilization and revenue potential.
Analysis Article Aug 18

Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

The STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) share price has fared very poorly over the last month, falling by a...
Analysis Article Aug 07

Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Jun 07

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

STRATA Skin Sciences, Inc.'s ( NASDAQ:SSKN ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong...
Analysis Article Mar 19

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Dec 31

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article Nov 03

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Jul 04

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Apr 18

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

STRATA Skin Sciences, Inc. ( NASDAQ:SSKN ) shareholders have had their patience rewarded with a 26% share price jump in...
Analysis Article Jan 14

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

SSKNUS Medical EquipmentUS Market
7D23.6%4.4%1.1%
1Y-94.2%-17.9%28.7%

Return vs Industry: SSKN underperformed the US Medical Equipment industry which returned -17.9% over the past year.

Return vs Market: SSKN underperformed the US Market which returned 28.7% over the past year.

Price Volatility

Is SSKN's price volatile compared to industry and market?
SSKN volatility
SSKN Average Weekly Movement27.9%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: SSKN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SSKN's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1989114Dolev Rafaeliwww.strataskinsciences.com

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne.

STRATA Skin Sciences, Inc. Fundamentals Summary

How do STRATA Skin Sciences's earnings and revenue compare to its market cap?
SSKN fundamental statistics
Market capUS$887.65k
Earnings (TTM)-US$6.26m
Revenue (TTM)US$30.70m
0.0x
P/S Ratio
-0.1x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SSKN income statement (TTM)
RevenueUS$30.70m
Cost of RevenueUS$12.82m
Gross ProfitUS$17.88m
Other ExpensesUS$24.14m
Earnings-US$6.26m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.06
Gross Margin58.25%
Net Profit Margin-20.40%
Debt/Equity Ratio527.8%

How did SSKN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 08:46
End of Day Share Price 2026/05/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

STRATA Skin Sciences, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCG Capital
Jeffrey CohenLadenburg Thalmann & Company
John SullivanLeerink Partners LLC